@article {7512,
	title = {A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma},
	journal = {American Journal of Hematology},
	volume = {90},
	year = {2015},
	note = {Cited By :31Export Date: 21 February 2017},
	month = {2015},
	pages = {42 - 49},
	abstract = {We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients with relapsed/refractory multiple myeloma in a randomized phase 2 study. Siltuximab was given by 6 mg/kg IV every 2 weeks. On progression, B was discontinued and high-dose dexamethasone could be added to S/plc. Response and progression-free survival (PFS) were analyzed pre-dexamethasone by European Group for Blood and Marrow Transplantation (EBMT) criteria. For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47\% (P = 0.213), complete response rate was 11 versus 7\%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103). Sustained suppression of C-reactive protein, a marker reflective of inhibition of interleukin-6 activity, was seen with S + B. Siltuximab did not affect B pharmacokinetics. Siltuximab/placebo discontinuation (75 versus 66\%), grade >=3 neutropenia (49 versus 29\%), thrombocytopenia (48 versus 34\%), and all-grade infections (62 versus 49\%) occurred more frequently with S + B. The addition of siltuximab to bortezomib did not appear to improve PFS or OS despite a numerical increase in response rate in patients with relapsed or refractory multiple myeloma. {\textcopyright} 2014 Wiley Periodicals, Inc.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84919683208\&doi=10.1002\%2fajh.23868\&partnerID=40\&md5=179d1a29102aeacb41c6374beee528dc},
	author = {Orlowski, R.Z. and Gercheva, L. and Williams, C. and Sutherland, H. and Robak, T. and Masszi, T. and Goranova-Marinova, V. and Dimopoulos, M.A. and Cavenagh, J.D. and {\v S}pi{\v c}ka, I. and Maiolino, A. and Suvorov, A. and Blad{\'e}, J. and Samoylova, O. and Puchalski, T.A. and Reddy, M. and Bandekar, R. and van de Velde, H. and Xie, H. and Rossi, J.-F.}
}
